Order Article Reprints

Lue K-H, Huang C-H, Hsieh T-C, Liu S-H, Wu Y-F, Chen Y-H. Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy. Cancers. 2022; 14(2):309. https://doi.org/10.3390/cancers14020309

Lue, Kun-Han, Chun-Hou Huang, Tsung-Cheng Hsieh, Shu-Hsin Liu, Yi-Feng Wu, and Yu-Hung Chen. 2022. "Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy" Cancers 14, no. 2: 309. https://doi.org/10.3390/cancers14020309

Lue, K.-H., Huang, C.-H., Hsieh, T.-C., Liu, S.-H., Wu, Y.-F., & Chen, Y.-H. (2022). Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy. Cancers, 14(2), 309. https://doi.org/10.3390/cancers14020309